AppId is over the quota
Main Category: Cancer / Oncology
Article Date: 24 Sep 2012 - 1:00 PDT Current ratings for:
Camptothecin Analog FL118 Shown To Inhibit Production Of Key Cancer Survival Genes
Some 500,000 people die of cancer in the United States each year, often because their cancers have become resistant to approved therapies. Scientists at Roswell Park Cancer Institute (RPCI) have made headway in the effort to overcome resistance to treatment, publishing findings about a novel cancer drug that has been shown to inhibit several genes associated with the ability of cancer cells to survive and reproduce.
A team led by Fengzhi Li, PhD, Associate Professor of Oncology in RPCI's Department of Pharmacology and Therapeutics, assessed the antitumor effects of FL118, a camptothecin analog that is structurally similar to irinotecan and topotecan, in preclinical studies.
The ability of cancers to resist treatment with chemotherapy or radiation is rooted in the tendency of tumor cells to overproduce key genes that enable cancer cells to survive, such as survivin, Mcl-1, XIAP and cIAP2. Dr. Li and his colleagues found that FL118 inhibits expression of these genes in cancer cells and ultimately causes those tumor cells to die.
They also found that cancer cells die in the presence of FL118 even when the cells contained no p53, a key tumor-suppressing gene product. Because this protein is functionally eliminated in many cancers, it is important that cancer cells are sensitive to FL118 regardless of their p53 function. Preclinical studies showed a complete loss of detectable tumor mass in animal models following treatment with FL118, even for tumors that did not express "wild-type" p53 - a level of efficacy rarely seen with standard cancer therapies.
Importantly, FL118 was equally effective against tumor cells that are not normally considered to be resistant to therapy, and showed no apparent toxicity at these therapeutic levels.
"Our studies show that FL118 may become a superior option for effective control of both early and late-stage cancer, with or without metastasis," said Dr. Li. "We still need to identify the exact biochemical targets as well as the pharmacokinetic and toxicological profile for FL118 before it goes into clinical studies, but we are encouraged by the implications of these compelling preclinical findings."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our cancer / oncology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:
MLA
27 Sep. 2012.
Please note: If no author information is provided, the source is cited instead.
'Camptothecin Analog FL118 Shown To Inhibit Production Of Key Cancer Survival Genes'
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Posts
0 comments: on "Camptothecin Analog FL118 Shown To Inhibit Production Of Key Cancer Survival Genes"
Post a Comment